Age-and sex-related interactions between insulin-like growth factor-I promoter polymorphisms and IGF-I levels

Open Neuroendocrinology Journal

Volumn 4, Issue , 2011, Pages 15-21

  van Turenhout, E C ^a   Deijen, J B ^b   Koppes, L L J ^c   van Mechelen, W ^a   Twisk, J W R ^a   Drent, M L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c TNO   (Netherlands)

Author keywords

Genotype; IGF I polymorphisms

Indexed keywords

SOMATOMEDIN C;

ADULT; AGE; ARTICLE; BODY MASS; CAUCASIAN; FEMALE; GENDER; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; LONGITUDINAL STUDY; MALE; ORAL CONTRACEPTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL;

EID: 79958100748     PISSN: None     EISSN: 18765289     Source Type: Journal    
DOI: 10.2174/1876528901104010015     Document Type: Article

References (47)

1. Froesch ER, Zapf J. Insulin-like growth factors and insulin: comparative aspects. Diabetologia 1985; 28: 485-93.
2. Arwert LI, Deijen JB, Drent ML. The relation between insulin-like growth factor I levels and cognition in healthy elderly: a metaanalysis. Growth Horm IGF Res 2005; 15: 416-22.
3. Becker AJ, Uckert S, Stief CG, Jonas U. Growth hormone, somatomedins and men's health. Aging Male 2002; 5: 258-62.
4. Arwert LI, Roos JC, Lips P, Twisk JW, Manoliu RA, Drent ML. Effects of 10 years of growth hormone (GH) replacement therapy in adult GH-deficient men. Clin Endocrinol (Oxf) 2005; 63: 310-16.
5. Chen W, Wang S, Tian T, et al. Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. Eur J Hum Genet 2009; 17: 1668-75.
6. Fletcher O, Gibson L, Johnson N, et al. Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14: 2-19.
7. Janssen JA, Lamberts SW. Igf-I and longevity. Horm Res 2004;62 Suppl 3:104-9.
8. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363: 1346-53.
9. Vaessen N, Heutink P, Janssen JA, et al. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 2001; 50: 637-42.
10. Harrela M, Koistinen H, Kaprio J, et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 1996; 98: 2612-15.
11. Hong Y, Pedersen NL, Brismar K, Hall K, de FU. Quantitative genetic analyses of insulin-like growth factor I (IGF-I), IGFbinding protein-1, and insulin levels in middle-aged and elderly twins. J Clin Endocrinol Metab 1996; 81: 1791-97.
12. Wagner K, Hemminki K, Forsti A. The GH1/IGF-1 axis polymorphisms and their impact on breast cancer development. Breast Cancer Res Treat 2007; 104: 233-48.
13. Weber JL, May PE. Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction. Am J Hum Genet 1989; 44: 388-96.
14. Rosen CJ, Kurland ES, Vereault D, et al. Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998; 83: 2286-90.
15. Rietveld I, Ikram MK, Vingerling JR, et al. An igf-I gene polymorphism modifies the risk of diabetic retinopathy. Diabetes 2006; 55: 2387-91.
16. te Velde SJ, van Rossum EF, Voorhoeve PG, et al. An IGF-I promoter polymorphism modifies the relationships between birth weight and risk factors for cardiovascular disease and diabetes at age 36. BMC Endocr Disord 2005;5:5.
17. Missmer SA, Haiman CA, Hunter DJ, et al. A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer. Int J Cancer 2002; 100: 332-6.
18. Frayling TM, Hattersley AT, McCarthy A, et al. A putative functional polymorphism in the IGF-I gene: association studies with type 2 diabetes, adult height, glucose tolerance, and fetal growth in U.K. populations. Diabetes 2002; 51:2313-6.
19. Giovannucci E, Haiman CA, Platz EA, Hankinson SE, Pollak MN, Hunter DJ. Dinucleotide repeat in the insulin-like growth factor-I gene is not related to risk of colorectal adenoma. Cancer Epidemiol Biomarkers Prev 2002; 11: 1509-10.
20. Jernström H, Deal C, Wilkin F, et al. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 2001; 10: 377-84.
21. Kato I, Eastham J, Li B, Smith M, Yu H. Genotype-phenotype analysis for the polymorphic CA repeat in the insulin-like growth factor-I (IGF-I) gene. Eur J Epidemiol 2003;18: 203-9.
22. Wen W, Gao YT, Shu XO, et al. Insulin-like growth factor-I gene polymorphism and breast cancer risk in Chinese women. Int J Cancer 2005; 113: 307-11.
23. Rietveld I, Janssen JA, Hofman A, Pols HA, van Duijn CM, Lamberts SW. A polymorphism in the IGF-I gene influences the agerelated decline in circulating total IGF-I levels. Eur J Endocrinol 2003; 148: 171-5.
24. Chen X, Guan J, Song Y, et al. IGF-I (CA) repeat polymorphisms and risk of cancer: a meta-analysis. J Hum Genet 2008; 53:227-38.
25. Kemper HC. Amsterdam Growth and Health Longitudinal Study (AGAHLS); a 23-Year Follow-up from Teenager to Adult about Lifestyle and Health. Medicine and Sport Science Basel: Karger; 2004; Vol. 47.
26. Maggio M, Ble A, Ceda GP, Metter, EJ. Decline in Insulin-like growth factor-I levels across adult life span in two large population studies. J Gerontol A Biol Sci Med Sci 2006; 61: 182-3.
27. Jernström H, Chu W, Vesprini D, et al. Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. Mol Genet Metab 2001; 72: 144-54.
28. Platz EA, Pollak MN, Rimm EB, et al. Racial variation in insulinlike growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers Prev 1999; 8: 1107-10.
29. Cnaan A, Laird NM, Slasor P. Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med 1997; 16: 2349-80.
30. Benjamini Y, Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995; 57: 289-300.
31. Morimoto LM, Newcomb PA, White E, Bigler J, Potter JD. Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: personal and lifestyle factors (United States). Cancer Causes Control 2005; 16: 917-27.
32. Cleveland RJ, Gammon MD, Edmiston SN, et al. IGF1 CA repeat polymorphisms, lifestyle factors and breast cancer risk in the Long Island Breast Cancer Study Project. Carcinogenesis 2006; 27: 758-65.
33. Allen NE, Davey GK, Key TJ, Zhang S, Narod SA. Serum insulinlike growth factor I (IGF-I) concentration in men is not associated with the cytosine-adenosine repeat polymorphism of the IGF-I gene. Cancer Epidemiol Biomarkers Prev 2002; 11: 319-20.
34. Capri M, Salvioli S, Sevini F, et al. The genetics of human longevity. Ann N Y Acad Sci 2006; 1067: 252-63.
35. Ceda GP, Dall'Aglio E, Maggio M, et al. Clinical implications of the reduced activity of the GH-IGF-I axis in older men. J Endocrinol Invest 2005; 28(11 Suppl Proceedings): 96-100.
36. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev 1993; 14: 20-39.
37. van Dam PS, Aleman A. Insulin-like growth factor-I, cognition and brain aging. Eur J Pharmacol 2004; 490: 87-95.
38. Peters DG, Kassam A, St Jean PL, Yonas H, Ferrell RE. Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. Stroke 1999; 30: 2612-2616.
39. Pearson CE, Nichol EK, Cleary JD. Repeat instability: mechanisms of dynamic mutations. Nat Rev Genet 2005; 6: 729-42.
40. Tran N, Bharaj BS, Diamandis EP, Smith M, Li BD, Yu H. Short tandem repeat polymorphism and cancer risk: influence of laboratory analysis on epidemiologic findings. Cancer Epidemiol Biomarkers Prev 2004;13: 2133-40.
41. Canzian F, McKay JD, Cleveland RJ, et al. Polymorphisms of genes coding for insulin-like growth factor I and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 2006; 94: 299-307.
42. Palles C, Johnson N, Coupland B, et al. Identification of genetic variants that influence circulating IGF1 levels: a targeted search strategy. Hum Mol Genet 2008; 17: 1457-64.
43. Patel AV, Cheng I, Canzian F, et al. Breast and Prostate Cancer Cohort Consortium. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS One 2008; 3(7): e2578.
44. Al-Zahrani A, Sandhu MS, Luben RN, et al. IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 2006; 15: 1-10.
45. Diorio C, Brisson J, Bérubé S, Pollak M. Genetic polymorphisms involved in insulin-like growth factor (IGF) pathway in relation to mammographic breast density and IGF levels. Cancer Epidemiol Biomarkers Prev 2008; 17: 880-8.
46. D'Aloisio AA, Schroeder JC, North KE, et al. IGF-I and IGFBP-3 polymorphisms in relation to circulating levels among African American and Caucasian women. Cancer Epidemiol Biomarkers Prev 2009; 18: 954-66.
47. Cheng I, DeLellis Henderson K, Haiman CA, et al. Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population. J Clin Endocrinol Metab 2007; 92: 3660-6.